Authors

Julio Pow-Sang, MD

Latest:

Dr. Julio Pow-Sang on Options for Low-and Intermediate-Risk Prostate Cancer

Jun Gong, MD

Latest:

Dr Gong on the Benefits and Limitations of PARP Inhibitor–Based Regimens in mCRPC

Jun Gong, MD, discusses the benefits and limitations of PARP inhibitor–based regimens in metastatic castration-resistant prostate cancer.

Juneko Grilley-Olson, MD

Latest:

Dr. Grilley-Olson on Treating Patients Based on Molecular Profile

Juneko Grilley-Olson, MD, assistant professor, UNC-Chapel Hill, Clinical Research, Thoracic Oncology Program, Head and Neck Oncology Program, Bone and Soft Tissue Oncology Program, UNC Lineberger Comprehensive Cancer Center, discusses treating patients with cancer based on their molecular profile.

Junji Matsui, PhD

Latest:

Anti-Proliferative Activity of Eribulin in Select Sarcoma Cell Lines

Junji Matsui, PhD, senior director, Eisai, discusses a preclinical study of eribulin (Halaven) demonstrating anti-proliferative activity in select soft tissue sarcoma cell lines.

Justin F. Gainor, MD

Latest:

Dr. Gainor on the Evolving Lung Cancer Armamentarium

Justin F. Gainor, MD, discusses the evolving lung cancer armamentarium.

Justin Gainor, MD

Latest:

Dr. Gainor on the Potential Value of Targeting TROP-2 and CEACAM5 in Lung Cancer

Justin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.

Justin Gallagher

Justin M. Balko, PharmD, PhD

Latest:

Justin Balko on JAK2 Amplification in TNBC

Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, describes a study that discovered JAK2 alterations in patients with treatment-refractory triple-negative breast cancer.

Justin N. Baker, MD

Latest:

Dr. Baker on Integrating Palliative Care into Pediatric Oncology

Justin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses integrating palliative care into the treatment of pediatric oncology.

Justin Taylor, MD

Latest:

Dr Taylor on the Integration of Tagraxofusp Into the Frontline Treatment Armamentarium for BPDCN

Justin W. Taylor, MD, discusses the evolution of frontline treatment options for patients with blastic plasmacytoid dendritic cell neoplasm, including the integration of tagraxofusp-erzs into the treatment armamentarium in this disease space.

Jyoti D. Patel, MD

Latest:

Dr. Patel on CheckMate-227 Results in Advanced NSCLC

Jyoti D. Patel, MD, discusses the results of the CheckMate-227 trial, which looked at an immunotherapy combination versus chemotherapy in patients with advanced non–small cell lung cancer.

Jyoti D. Patel, MD Northwestern&nbsp

Jyoti D. Patel, MD NorthwesternÂ

Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center

Latest:

TRK Inhibitors in Lung and GI Cancers

Jyoti D. Patel, MD, University of Chicago

Jyoti Malhotra, MD, MPH

Latest:

Dr. Malhotra on Challenges with Precision Medicine in Advanced Solid Tumors

Jyoti Malhotra, MD, MPH, discusses challenges with precision medicine in advanced solid tumors.

Jyoti Patel, MD

Latest:

Dr Patel on Findings From the TRUST-II Trial in ROS1+ NSCLC

Jyoti Patel, MD, discusses the implications of the TRUST-II trial in locally advanced or metastatic ROS1-positive NSCLC, regardless of prior TKI exposure.

K. Michael Cummings, PhD, MPH

Latest:

Helping Cancer Patients Quit Smoking Should Be a Standard of Care

Most oncologists do not regularly provide evidence-based tobacco cessation support for patients with cancer who smoke. However, addressing tobacco use is not as difficult as some might think.

Kabir Mody, MD

Latest:

Dr. Mody on Progress Made With Y-90 in Hepatocellular Carcinoma

Kabir Mody, MD discusses new directions with yttrium-90 glass microspheres in hepatocellular carcinoma as demonstrated in the retrospective LEGACY study.

Kabir Mody, MD, Mayo Clinic Cancer Center